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Abstract
Background: Interleukin-17 (IL-17) is a novel cytokine secreted by activated human memory CD4+ T cells. In vivo IL-17
recruits neutrophils into the airways via the release of CXC chemokines (interleukin-8) from bronchial epithelial cells.
Since neutrophils are implicated in pathogenesis of chronic obstructive pulmonary disease (COPD), chronic bronchitis
(CB) and asthma, we hypothesized thattherewould be increased concentration of IL-17 in the airways of these patients.
To test this hypothesis, we measured levels of IL-17 in induced sputum of COPD patients, chronic bronchitis and asth-
matics and compared themwith healthy controls.Methods: Levels of IL-17 in induced sputumweremeasured via ELISA
method in19 COPD,16 CB,10 asthma and11control subjects. Airwayresponsiveness tomethacholinewasperformed in
people with FEV1 higher than 70% of predicted. Results:There were no significant differences in IL-17 levels between
control group and the other groups.However, levels of IL-17 in sputum of COPD patientswere significantly lower than
in asthma (P=0.004) andin CB (P=0.01) groups.Medians and (ranges) were as follows: asthmaF37.6 pg/ml (18.8^55.7 pg/
ml),CB 29.3 pg/ml (18.8^49.7 pg/ml) and COPD 24.6 pg/ml (0-34.1pg/ml).Comparison of healthy control subjects (PC20
48mg/ml) to a groupwith bronchial hyperreactivity, which consisted of asthmatics and CB patients, whose PC20 was
less than 8mg/ml, revealedthatlevelsof IL-17were significantlyincreasedinthe secondgroup (P=0.02).Also, levels of IL-
17 were significantly increased (P=0.02) in the asthmatic patients with bronchial hyperreactivity compared to healthy
subjects.Moreover levels of IL-17 in sputum of all studied subjects correlated negatively with PC20 (r=0.51, P=0.002).
Conclusions:According to ourresults IL-17 isprobablynotinvolvedinpathogenesisof stableCOPD, butitmayplayarolein
peoplewith airwayhyperresponsiveness. r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2003.1507, available online at http://www.sciencedirect.com
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Bronchial asthma, chronic obstructive pulmonary dis-
ease (COPD) and chronic bronchitis (CB) are di¡erent
chronic diseases, but in£ammation of the airways is im-
portant in pathogenesis of all these conditions. Although
mechanisms fordevelopmentof these diseases are di¡er-
ent, both recruitment and activation of neutrophils
seems important in all these conditions (1^5). Neutro-
phils are capable of producing proteolytic enzymes and
free oxygen radicals, whichmay contribute to the devel-
opment of airway obstruction, especially in COPD pa-
tients but also in asthmatics (6,7). T-cells are very likely
to control the recruitment of granulocytes (especially
eosinophils but also neutophils) into the airways in ob-
structive airway diseases. For asthma, this has been
shown in animal models, but not as yet in COPD (8).Received1February 2002, accepted in revised from 28 October 2002
Correspondence should be addressed to: Adam Barczyk,Department
of Pneumology, Silesian Medical Academy,Katowice, ul.Medykow14,
Poland.Fax: +48-32-252 38 31; E-mail: adagneic@hotmail.comThere are also some suggestions that T-cells can deter-
mine airway hyperresponsiveness (AHR) via recruitment
and activation of neutrophils (9).
Interleukin-17 (IL-17) is a novel cytokine secreted only
by activatedCD4+ andCD8+ humanmemoryT cells (10,
11). Both theTh1 and Th2 subsets of CD4+ cells release
IL-17.However, IL-17 receptor is widely distributed and is
expressed in almost all tissues, including the lung, and on
several cells, includingbronchial epithelial cells (12).There
is increasingevidence that IL-17 is a potentcytokinemed-
iating in£ammatory responses in various tissues.
In human lung, it was shown that IL-17 induces IL-1b
and TNF-a production (13). IL-17 is also important for
host defence against bacteria infection. IL-17R knockout
mice displayed a signi¢cant delay in neutrophil recruit-
ment into the alveolar space after K. pneumoniae infec-
tion (14). IL-17 may indirectly recruit neutrophils into the
airways via the release of mediators from other airway
cells (15) (e.g. by the release interleukin-8 frombronchial
epithelial cells (16) or by induction of release of endogen-
ous tachykinins acting via NK-1 receptors (17)). Thus,
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cruitment and activation of neutrophils.
Since neutrophils are implicated in pathogenesis of
chronic obstructive pulmonary disease (COPD), chronic
bronchitis and asthma, we hypothesized that there
would be increased concentration of IL-17 in the airways
of these patients. To test this hypothesis, we measured
levels of IL-17 in induced sputum of COPD patients,
chronic bronchitis and asthmatics and compared them
with healthy controls.
MATERIALANDMETHODS
Subjects
The studyprotocolwas approvedbyethics committee of
the Silesian Medical Academy. All subjects gave written
informed consent before they entered the study.
Nineteen patients with COPD were studied. All pa-
tients developed symptoms after the age of 40, andwere
currentor ex-smokerswith at least10 pack-year smoking
history. All patients had FEV1/VC of less than 70 percent
of predicted, FEV1 of less than 85 percent of predicted
and reversibility of bronchial obstruction of less than 10
percentof predicted,15min after 200mgof inhaled salbu-
tamol. Exclusion criteria were: history of atopy; exacer-
bation of COPD or use of systemic steroids during 4
weeks before the study. Five COPD patients were not
treated.Others receivedconventional COPD treatment:
anticholinegic agents, xanthines, short-and long-acting
b2-agonists. Seven of them were additionally treated
with inhaled steroids (budesonide 200^1200mg/day).
Sixteen patients with CB had to ful¢ll the following
criteria: presence of cough and sputum production for
mostdays for at least 3 consecutivemonths during 2con-
secutive years; no present or past history of other dis-
eases of the lung (including asthma and its symptoms,
such as wheezing or dyspnoea at night), whichmay cause
identical symptoms as CB; reversibility of bronchial ob-
struction of less than10 percentof predicted,15min after
200mgof inhaled salbutamol (performed in subjectswith
FEV1of less than 90 percent of predicted); no atopic his-
tory; no exacerbation of CB or use of systemic steroids
during 4 weeks before the study. Among all chronic
bronchitis patients only one was treated (anticholineric
drug and long acting b2-agonist).
Ten patients with bronchial asthma have been studied.
The inclusion criteria were the following: diagnosed
bronchial asthma; reversibility of bronchial obstruction
15min after delivery of 200mg of inhaled salbutamol of
more than12 percent (performed in subjects with FEV1
of less than 90 percent of predicted); bronchial hyper-
reactivity to methacholineFPC20 o8mg/ml (per-
formed in subjects with FEV1of more than 70 percent of
predicted); no exacerbation of asthma or use of systemic
steroids during 4 weeks before the study.Three out of10asthmatics recruited to the study were not treated.Five
asthma patients were treated with inhaled steroids (bu-
desonide 400^800mg/day).
The control group consisted of 11 healthy volunteer
subjects without any respiratory symptoms or diseases.
The additional exclusion criteria included: abnormal
spirometry; bronchial hyperreactivity to methacholine
(PC20o8mg/ml); history of atopy; respiratory infection
during 4 weeks before the study. Neither of eleven
healthy subjects received treatment.
Lung function
Lung function was measured with dry spirometer (Mas-
terLab, Jaeger, Germany). Reversibility of bronchial ob-
struction (spirometry, before and15min after inhalation
of 200mg of salbutamol) was performed in asthmatics
and in all COPD patients.
Sputum induction andprocessing
Sputum induction and processing was performed ac-
cording a previously described method (18). First, spiro-
metry was performed before and15min after inhalation
of 200 mg of salbutamol.Then subjects inhaled 7ml of 5%
saline at room temperature from an ultrasonic nebulizer
(Thomex MB, Medbryt, UK). After mouthwashing they
were encouraged to cough sputum. If unsuccessful, they
repeated (maximal twice) the above procedure and per-
formed spirometry every time. Sputumwas poured into
a Petri dish and all portions that macroscopically ap-
peared free of salivary contamination were separated
from saliva using blunted forceps. This selected portion
was weighed and 4 times the volume of dithiothreitol
(DTT) (GibcoBRLultra pure)were added to the sputum.
Themixturewas vortexed and repeatedly aspirated and
then placed in a bench rocker for 20min. After this, a
volume of D-PBS (Gibco-BRL), equal to the volume of
sputum and DTTwere added, and mixture was rocked
for 5min.Themixture was then centrifuged at 790g for
10min and the supernatant was aspirated and stored in
Eppendorf tubes at701C for later assay.The cell pellets
from sputumcentrifugationwere resuspended inD-PBS.
Using a Neubauer hemocytometer, the following were
measured: a total cell count of leukocytes, percentage
of epithelial cells and cell viability (by the trypan blue
exclusion method). Slides were prepared by using
a Cytospin instrument (HPW 342). Two slides were
stainedwith May^Grunwald^Giemsa stain for di¡eren-
tial cell counts. Percentage of macrophages, neutrophils,
lymphocytes and eosinophils were determined after
counting of 400 leukocytes.
Bronchial responsiveness
At least 24h after sputum induction, bronchial respon-
siveness tomethacholinewasperformedaccording Sterk
728 RESPIRATORYMEDICINEetal.’s standards inhealthy subjects,CBpatients and asth-
matics.PC20wasmeasuredby inhalation ofmethacholine
(with doubling concentrations: 0.03^25mg/ml) delivered
by an ultrasonic nebulizer (Thomex MB, Medbryt, UK)
with maximal output. Each concentration was delivered
for 2min and was followed by FEV1 measurement. The
test was stoppedwhen therewas a fall in FEV1of 20 per-
cent compared with initial values or when the maximal
concentration was inhaled. The PC20 value was calcu-
lated by interpolation from a line, which connected the
last two dose^response points (19).
Measurement of IL-17 levels
Concentrations of IL-17 in supernatant of induced spu-
tum were determined by ELISA method using commer-
cially available kit (R&Dsystems). The detection limit of
the assay was15pg/ml.
Control experiments
Reproducibility of the assay for IL-17 measurements was
carried out with six replicates of induced sputum sam-
ples from 8 patients.To examine the e¡ect of DTTon IL-
17 assay, the spikerecovery was evaluatedby spiking four
levels of IL-17 into induced sputum from two di¡erent pa-
tients.The concentration of DTT in induced sputumwas
the same as in the study (0.05%). Additionally, in£uence
of di¡erent concentrations of DTT (0.01, 0.05, 0.1 and
0.2%) on normal and ‘‘spiked’’ induced sputum was
checked. All measurements were performed in dupli-
cate.
Statistical analysis
Values are expressed as median (maximal and minimal
values are inbrackets).Di¡erencesbetween the four stu-
diedgroupswere ¢rst analyzedusing theKruskal^Wallis
test. If signi¢cant, inter-group comparisons were per-
formed using Mann^Whitney U-test.Correlations were
determinedusing Spearman rank correlation.P values of
o 0.05 were accepted as signi¢cant.
RESULTS
The17 persons repeated the sputum induction after the
¢rst 7ml of solution once and the 31 persons twice.
There were no di¡erences between the four studied
groups concerning these variables (P=0.13, Kruskal^
Wallis test). Also, the concentrations of IL-17 did not dif-
fer between the groups of persons who repeated the in-
duction once, twice or did not repeat it at all (P=0.44,
Kruskal^Wallis test).
Demographic dates, spirometry andbronchial respon-
siveness results are shown inTable1.Induced sputum of COPD patients was characterized
by signi¢cantly increasednumber andpercentage of neu-
trophils (respectively P=0.02 and P=0.03) and eosinophils
(respectively P=0.02 and P=0.04) as compared to healthy
subjects. Asthmatics in comparison with control sub-
jects had a signi¢cantly increased number (P=0.003) and
percentage (P=0.0002) of eosinophils in their induced
sputa. The number and percentage of neutrophils were
signi¢cantly decreased in induced sputum of asthmatics
compared to COPD patients (P=0.0003 and P=0.0002,
respectively) and CB patients (P=0.001 and 0.0009, re-
spectively). The cell viability did not di¡er between the
studied groups and, with the exception of two persons,
it was higher than 65%.The characteristics of sputum of
the studied population is shown inTable 2.
Levels of IL-17 in induced sputum were detected in all
subjects. The Kruskal^Wallis test for levels of IL-17 in
supernatant of induced sputum for all four studied
groupswas statistically signi¢cant (P=0.007).There were
no signi¢cant di¡erences in IL-17 levels between the con-
trol group and other groups. However, levels of IL-17 in
sputum of COPD patients were signi¢cantly lower than
in asthma (P=0.004) and in CB (P=0.01) groups (Fig. 1).
Medians and (ranges) were as follows: asthmaF37.6pg/
ml (18.8^55.7 pg/ml),CB 29,3 pg/ml (18.8^49.7 pg/ml) and
COPD 24.6pg/ml (0^34.1pg/ml). Comparison of healthy
control subjects (PC2048mg/ml) to a groupwith bron-
chial hyperreactivity, which consisted of asthmatics and
CB patients, whose PC20was less than 8mg/ml, revealed
that levels of IL-17 were signi¢cantly increased in second
group (P=0.02) (Fig. 2). Also, levels of IL-17 were signi¢-
cantly increased (P=0.02) in the asthmatic patients with
bronchial hyperreactivity compared to healthy subjects.
Moreover, levels of IL-17 in sputum of all subjects with
FEV1 470 percent of predicted correlated negatively
with PC20 (r=0.51, P=0.002) (Fig. 3). In the asthma
group, the percentage of macrophages in sputum corre-
lated negatively with levels of IL-17 (r=0.84, P=0.003).
The reproducibility of the assay was good.The overall
coe⁄cient of variation has been calculated to be 2.4%
(range1.3^3.5%).
The average recovery of ‘‘spiked’’ IL-17 from induced
sputum of two studied patients were 88.2 and 66.3%.
The percentage of recovered IL-17 depended on the
amount of ‘‘spiked’’ IL-17 (the more ‘‘spiked’’ IL-17 the
higher the recovery rate). The results of ‘‘spike’’ experi-
ments are shown inTable 3.
DTT decreased levels of IL-17 in supernatant of
induced sputum and this e¡ect was dose-dependent.
However, the in£uence of DTT on levels of IL-17
was weak when used in a typical concentration (0.05%).
With this concentration, the levels of IL-17 in induced
sputumwere decreased by DDT by approximately 20%.
The results of in£uence of various concentrations of
DTT on measurements of IL-17 in induced sputum are
shown in Fig. 4.
TABLE 1. Characteristics of study subjects
Group Control Asthma CB COPD
Subject number 11 10 16 19
Age (years) 48.0 58.0 63.5 64.0
(24.0^72.0) (27.0^67.0) (44.0^79.0) (48.0^74.0)
Sex (M/F) (10/1) (3/7) (11/5) (14/5)
Cigarette smoking (3/3/5) (1/3/6) (3/9/4) (5/14/0)
(Y/Ex/N)
FEV1 (% pred) 110.6 75.0 92.1 45.5
(101.0^142.0) (64.4^111.3) (73.9^127.0) (22.6^82.6)
FEV1%FVC 87.3 66.9 78.4 51.6
(78.9^98.5) (54.5^88.8) (65.1^87.9) (36.1^67.0)
DFEV1after salbutamol (% pred) n.d. 20.7 3.1 3.1
(13.6^34.7) (0^9.7) (0^8.3)
PC20 methacholine 425.0 0.1 6.1 n.d.
(mg/ml) (18.6^425.0) (0.07^0.38) (0.4^425.0)
Data are expressed as medians and ranges; MFmales, FFfemales; YFcurrent cigarette smokers, ExFex-smokers,
NFnonsmokers;FEV1 (% pred)Fforcedexpiratory volumein1s (percentage ofpredictedvalue);FVCFforcedvitalcapacity;
DFEV1after salbutamol (% pred)Freversibilityof airwayobstruction15min afterdelivering 200 mgof salbutamol expressed as
percentage of predicted value; PC20 methacholine (mg/ml)Fprovocative concentration of methacholine causing a 20% fall in
FEV1; n.d.Fnotdone.
TABLE 2. Characteristics of induced sputumfromthe studypopulation
Group Control Asthma CB COPD
Total cells* 2.1 1.7 4.6 4.2
(x106/g of sputum) (0.2^10.9) (0.7^7.7) (1.2^14.1) (1.1^64.0)
Viability (%) 81 82 85 87
(47^95) (74-89) (40^96) (74^95)
Macrophages (%)* 36.0 33.2 29.3 16.9
(19.2^87.9) (11.6^54.4) (3.1^54.7) (5.5^66.8)
Neutrophils (%)** 62.0 33.3 59.6 74.0
(9.8^79.0) (7.3^64.2) (24.0^94.1) (29.6^92.2)
Eosinophils (%)* * 0.5 27.3 1.6 2.7
(0^14.2) (3.0^80.0) (0.2^48.0) (0^33.7)
Lymphocytes (%) 1.7 2.5 2.4 1.2
(0.2^7.0) (0^14.4) (0.6^8.9) (0^8.9)
Epithelial cells (%)* 9.4 7.5 4.5 2.8
(0^35.0) (0.8^22.7) (1.3^10.7) (0^17.5)
Data are expressedasmedians andranges. *Po0.05, **Po0.0005 fordi¡erencesbetweenthe fourgroups,Kruskal^Wallis.
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Interleukin-17,T-lymphocyte-related cytokine is thought
to link activation of certainT-lymphocytes with the re-
cruitment and activation of airway neutrophils (8). Neu-
trophils seem to be important in pathogenesis of
bronchial asthma, chronic bronchitis and especially in
COPD (2,3). In COPD, and in CB patients, the number
of neutrophils has been shown to be increased in induced
sputum (20), in broncho-alveolar lavage (BAL) £uid
(21,22) butnot inbronchialmucosa (2). IL-17 recruits neu-trophils into the airways indirectly, by the release of in-
terleukin-8 from bronchial epithelial cells (16). Several
studies showed that levels of interleukin-8 in induced
sputum of COPD patients are increased (23,24). Based
on these studies we presumed that levels of IL-17 might
be increased in induced sputum of COPD patients and
also in CB patients and asthmatics. However, results of
our study showed that levels of IL-17 in induced sputum
of COPD patients compared to healthy subjects were
not increased, but in fact decreased, although it was
not statistically signi¢cant. These results may suggest
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FIG. 3. Correlation between bronchial hyperreactivity to
methacholine and levels of IL-17 in induced sputum.
TABLE 3. Recovery of ‘‘spiked’’ IL-17 from induced
sputum
Concentration of
‘‘spiked’’IL-17 in induced
sputum (pg/ml)
Recoveryof IL-17 (%)
Patient1 Patient 2
100 75.8 32.8
250 71.3 64.5
500 89.2 60.1
1000 116.5 107.8
730 RESPIRATORYMEDICINEthat IL-17 is probably not involved in the pathogenesis of
stable COPD.However, IL-17mayplay a role in triggering
exacerbation of COPD (8). It is possible that levels of IL-
17 may be increased even in stable COPD patients when
studied in BAL or bronchialmucosa, because the results
using these techniques are di¡erent to those using in-
duced sputum (25).
Levels of IL-17 in induced sputum were not signi¢-
cantly increased in asthma patients (P=0.08) and CB
patients (P=0.17). However when compared to COPD
patients, levels of IL-17 were signi¢cantly increased inCB patients and especially in asthmatics. We speculate
that it may be connected with an activation of CD4+
subset of T-lymphocytes, which are the main source
of IL-17.CD4+ T-lymphocytes play a role in pathogenesis
of bronchial asthma (26), in opposition to CD8+
T-lymphocytes, which are implicated in pathogenesis of
COPD (27). There is also an additional explanation. As
was recently shown, eosinophils from asthmatics are
able to produce IL-17 (28). So, the increased number and
activation of eosinophils in asthmatics may be responsi-
ble for increased concentration of IL-17 in induced spu-
tum of these patients as compared to patients with
COPD.
Airway hyperresponsiveness is a typical feature of
asthma.Clinical studies have shown the relationship be-
tween activated in£ammatory cells (including lympho-
cytes T, eosinophils and neutrophils) and airway
hyperresponsiveness (29,30). Through the release of cy-
tokines (mainlyTh2 but also others),T cells can produce
AHRindirectlybypromoting therecruitment and subse-
quent activation of eosinophils and neutrophils (8,9,31). In
our study we showed that levels of IL-17 were increased
in asthmatics with AHR compared to the control group.
Moreover, levels of this cytokine correlated positively
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FIG. 4. In£uence of di¡erent concentrations of DTTon mea-
surements of IL-17 in‘‘spiked’’induced sputum.
INTERLEUKIN-17 INSPUTUMCORRELATESWITHAIRWAY 731with a degree of AHR. These results indicate that IL-17
together with other cytokines produced by T lympho-
cytes may promote the development of AHR by activa-
tion and recruitment of granulocytes. However, further
clinical studies are needed to con¢rm this hypothesis.
Negative correlation between IL-17 and sputum
macrophages in asthma could suggest some connection
between them.However, we think that it re£ected only
the in£uence of IL-17 on the other cells in induced sputum
(there is a positive correlationbetween levels of IL-17 and
the sum of the percentages of neutrophils, eosinophils
and lymphocytes, r=0.84, P=0.003). Moreover, further
analysis showed that only neutrophils and eosinophils
are important for the existence of that correlation be-
cause IL-17 correlated only with the sum of neutrophils
and eosinophils (r=0.77, P=0.009), but not with the sum
of lymphocytes with either eosinophils or neutrophils.
We think that these results further support the poten-
tial association between IL-17 and the activation and re-
cruitment of granulocytes in asthmatic patients.
The group of patients with chronic bronchitismay ap-
pear heterogeneous because some of them have airway
hyperresponsivenes, the percentage of eosinophils in
sputum is up to 48% and some of them are non-smokers.
However, we think that all16 chronic bronchitis patients
were correctly diagnosed. All of them have characteris-
tic symptoms of chronic bronchitis. Exclusion of other
diseases, which could cause chronic productive cough,
wasbased on a detailedhistory taken according to a spe-
cially designed protocol. Special e¡ort was made not to
qualify to the study the patients with a history of any
symptoms characteristic of asthma, such as: wheezing
or dyspnoea at night.
Some authors, in order to better distinguish patients
with chronic bronchitis from asthmatics, do not qualify
to the CB group the patients withmore than 5% eosino-phils in sputum or with a greater than10^15% improve-
ment in FEV1 after treatment with bronchodilator (32^
34). In our study, we performed the bronchial reversibil-
ity test after salbutamol only in part of CB patients (with
FEV1 less than 90% predicted), because we think that
performing this test in patientswithouteven slight bron-
chial obstruction has no diagnostic value. All CB patients
who had performed a bronchial reversibility test had its
value of less than10% predicted.We did not exclude pa-
tients with sputum eosinophilia from our study. How-
ever, 15 patients had less than 4% of eosinophils in
sputum. The only one patient who exceeded this limit
had 48% of eosinophils in sputum. He is a life-long ex-
smoker, who smoked one pack of cigarettes per day for
50 years and stopped smoking 7 years ago. His ¢rst
symptoms of chronic productive cough started 5 years
ago at the age of 65.His reversibilityofbronchial obstruc-
tion after salbutamol was 3.2% predicted and his PC20
was 4.8 mg/ml. In our opinion his age, smoking history,
no asthmatics symptoms in history, poor reversibility in-
dicate very little probability of coexistence of asthma
with chronic bronchitis. However, we also performed a
statistical analysis without this patient, to check his im-
pact on results.This analysis showed that di¡erences are
still signi¢cant (increased levels of IL-17 in CB compared
to COPD (P=0.02), increased levels of IL-17 in a group
with bronchial hyperreactivity compared to healthy con-
trol subjects (P=0.03) and a negative correlationbetween
levels of IL-17 and PC20 (r=0.52, P=0.002)).
The mean PC20 for the CB group was 10.8mg/ml and
the median was 6.1mg/ml (range 0.4^25mg/ml). These
data indicate that part of our CB patients had mild-to-
moderate airways hyperresponsiveness. However, a
comparison with data from literature shows that range,
distribution andmeanof PC20 ofCBpatients in our study
is typical of values seen in chronic bronchitis (32^36). Fi-
nally, although chronic bronchitis is more prevalent
among smokingpatients, itmay alsobe found innonsmo-
kers.
The percentage of neutrophils in induced sputum of
normal subjects is higher in our study compared to the
literature.We think that it may be a result of the in£u-
ence of air pollution. Katowice is a capital of a coal-
mining region, which is the most air-polluted place in
Poland. Additionally, some of our healthy volunteers are
retired coal-miners, whoworked in coalmines for more
than 20 years. Of course, some of them smoked, too.
They did not have any symptoms of lung diseases. How-
ever, although thepercentage of neutrophils in sputumof
healthy volunteers in our study was relatively high, it
was still signi¢cantly lower than in COPD group.
Our control experimentswith the in£uence ofDTTon
the assaymeasurements showed that levels of IL-17 in in-
duced sputum measured by ELISA method in the pre-
sence of 0.05% DTTwere decreased compared to real
levels, but this e¡ectwas relatively weak (approximately
732 RESPIRATORYMEDICINEa 20% decrease). Additionally, this e¡ect was the same
for all studiedgroups, so it did not have any e¡ect on sta-
tistical analysis.
According to our results, IL-17 is probablynot involved
in pathogenesis of stable COPD, but itmay play a role in
patients with bronchial hyperreactivity.
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